The current treatment strategies in advanced malignancies remain limited. Notably,
immunotherapies have raised hope for a successful control of these advanced diseases, but …

Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis
and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC) …

Immunotherapy with immune checkpoint blockade (ICB) has shown limited benefits in
hepatocellular carcinoma (HCC) and other cancers, mediated in part by the …

Despite centuries since the discovery and study of cancer, cancer is still a lethal and
intractable health issue worldwide. Cancer-associated fibroblasts (CAFs) have gained much …

The success of atezolizumab plus bevacizumab treatment contributed to a shift in systemic
therapies for hepatocellular carcinoma (HCC) towards combinations that include cancer …

Recently, immune checkpoint inhibitors (ICIs) therapy has become a promising therapeutic
strategy with encouraging therapeutic outcomes due to their durable anti-tumor effects …

The immune system has crucial roles in cancer development and treatment. Whereas
adaptive immunity can prevent or constrain cancer through immunosurveillance, innate …

Glioblastoma (GBM) is an incurable primary malignant brain cancer hallmarked with a
substantial protumorigenic immune component. Knowledge of the GBM immune …

The emergence of immune checkpoint blockade therapies over the last decade has
transformed cancer treatment in a wide range of tumor types. Unprecedented and durable …

Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide.
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …